A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study

Pappo, A.S.; Vassal, G.; Crowley, J.J.; Bolejack, V.; Hogendoorn, P.C.W.; Chugh, R.; ... ; Helman, L.J. (2014)

Article / Letter to editor

• sarcoma
• IGF-1R
• SARC
• insulin-like growth factor

• All authors: Pappo, A.S.; Vassal, G.; Crowley, J.J.; Bolejack, V.; Hogendoorn, P.C.W.; Chugh, R.; Ladanyi, M.; Grippo, J.F.; Dall, G.; Staddon, A.P.; Chawla, S.P.; Maki, R.G.; Araujo, D.M.; Geoerger, B.; Ganjoo, K.; Marina, N.; Blay, J.Y.; Schuetze, S.M.; Chow, W.A.; Helman, L.J.
• Date: 2014-08-15
• Journal: Cancer
• Volume: 120
• Issue: 16
• Pages: 2448 - 2456
• DOI: doi:10.1002/cncr.28728